title: Human telomerase reverse transcriptase promoter-driven oncolytic adenovirus with E1B-19 kDa and E1B-55 kDa gene deletions.
abstract: We constructed an oncolytic adenovirus, Adeno-hTERT-E1A, with deletions of the viral E1B, E3A, and E3B regions and insertion of a human telomerase reverse transcriptase (hTERT) promoter-driven early viral 1A (E1A) cassette that confers high transcriptional activity in multiple human tumor cell lines. The oncolytic potential of Adeno-hTERT-E1A was characterized in comparison with that of the E1B-55 kDa- and E3B-region-deleted oncolytic adenovirus ONYX-015. Tumor cells infected with Adeno-hTERT-E1A expressed dramatically higher levels of E1A oncoprotein, underwent enhanced lysis, and displayed an earlier and higher apoptotic index than cells infected with ONYX-015. Despite the increase in virus-induced apoptotic death, Adeno-hTERT-E1A replicated and produced functional progeny leading to viral spread, but with reduced efficiency compared with ONYX-015, in particular in A549 cells. Virus-induced E1A expression, host cell apoptosis, viral hexon protein production, and DNA synthesis were markedly reduced in primary human hepatocytes after infection with Adeno-hTERT-E1A as compared with ONYX-015. The strong oncolytic activity of Adeno-hTERT-E1A in tumor cell culture translated into superior antitumor activity in vivo in an MDA-MB-231 solid tumor xenograft model. Adeno-hTERT-E1A thus has strong therapeutic potential and an improved safety profile compared with ONYX-015, which may lead to reduced toxicity in the clinic.
authors.affiliation: Division of Cell and Molecular Biology, Department of Biology, Boston University, Boston, MA 02215, USA.
authors.forename: Joshua C
authors.initials: JC
authors.lastname: Doloff
authors.forename: David J
authors.initials: DJ
authors.lastname: Waxman
authors.forename: Youssef
authors.initials: Y
authors.lastname: Jounaidi
mesh_terms: D000256:Adenoviridae / Q000235:genetics*; D017501:Adenovirus E1B Proteins / Q000235:genetics*; D001483:Base Sequence; D002460:Cell Line; D017931:DNA Primers; D017353:Gene Deletion; D006801:Humans; D050130:Oncolytic Virotherapy; D016133:Polymerase Chain Reaction; D011401:Promoter Regions, Genetic; D019098:Telomerase / Q000235:genetics*
chemical_list: D017501:Adenovirus E1B Proteins; D017931:DNA Primers; D019098:Telomerase
references.citation: Cell. 1981 Oct;26(2 Pt 2):213-20
references.pmid: 7332929
references.citation: Science. 1994 Dec 23;266(5193):2011-5
references.pmid: 7605428
references.citation: Virology. 2003 Jan 20;305(2):378-87
references.pmid: 12573583
references.citation: Annu Rev Cell Dev Biol. 2006;22:531-57
references.pmid: 16824017
references.citation: J Biol Chem. 1999 Aug 20;274(34):23777-86
references.pmid: 10446138
references.citation: J Virol. 2001 Jun;75(12):5443-7
references.pmid: 11356950
references.citation: Science. 1996 Oct 18;274(5286):373-6
references.pmid: 8832876
references.citation: Hum Gene Ther. 2001 Jul 1;12(10):1323-32
references.pmid: 11440625
references.citation: Oncogene. 1998 Jan 22;16(3):349-57
references.pmid: 9467960
references.citation: Cancer Gene Ther. 2005 Feb;12(2):141-61
references.pmid: 15472714
references.citation: Cell. 2000 Jan 7;100(1):57-70
references.pmid: 10647931
references.citation: Cancer Gene Ther. 2007 Feb;14(2):139-50
references.pmid: 17139321
references.citation: Cancer Res. 1999 Feb 15;59(4):826-30
references.pmid: 10029071
references.citation: Int J Oncol. 2002 Dec;21(6):1161-74
references.pmid: 12429964
references.citation: Curr Cancer Drug Targets. 2007 Mar;7(2):133-9
references.pmid: 17346104
references.citation: Cancer Gene Ther. 2004 Sep;11(9):585-93
references.pmid: 15338010
references.citation: Hum Gene Ther. 2007 Sep;18(9):773-86
references.pmid: 17725410
references.citation: Breast Cancer Res Treat. 2003 Feb;77(3):277-84
references.pmid: 12602927
references.citation: Biochem Pharmacol. 1995 May 26;49(11):1691-701
references.pmid: 7786310
references.citation: Nat Genet. 1992 Aug;1(5):372-8
references.pmid: 1302034
references.citation: J Biol Chem. 2007 Sep 7;282(36):26460-70
references.pmid: 17630431
references.citation: Cancer Res. 1996 Mar 15;56(6):1331-40
references.pmid: 8640822
references.citation: Genes Dev. 1996 Feb 15;10(4):461-77
references.pmid: 8600029
references.citation: Cancer Res. 1998 Oct 1;58(19):4391-401
references.pmid: 9766669
references.citation: Oncogene. 2006 Jan 5;25(1):61-9
references.pmid: 16170363
references.citation: Oncogene. 1999 Aug 12;18(32):4523-9
references.pmid: 10467396
references.citation: Cancer Res. 2001 Jun 1;61(11):4437-44
references.pmid: 11389073
references.citation: Oncogene. 1999 Jan 28;18(4):955-65
references.pmid: 10023671
references.citation: Mol Cancer Res. 2003 Aug;1(10):739-46
references.pmid: 12939399
references.citation: Mol Cancer Ther. 2003 Dec;2(12):1313-9
references.pmid: 14707272
references.citation: Cancer Gene Ther. 1999 Jul-Aug;6(4):367-72
references.pmid: 10419055
references.citation: J Virol. 2006 Feb;80(4):2000-12
references.pmid: 16439556
references.citation: Cancer Res. 2004 Jan 1;64(1):292-303
references.pmid: 14729637
references.citation: Int J Oncol. 1999 Dec;15(6):1163-8
references.pmid: 10568823
references.citation: Gene. 2001 May 16;269(1-2):1-12
references.pmid: 11376932
references.citation: Mol Cell Biol. 1992 Jun;12(6):2570-80
references.pmid: 1317006
references.citation: Curr Cancer Drug Targets. 2007 May;7(3):285-301
references.pmid: 17504125
references.citation: Cancer Cell. 2004 Dec;6(6):611-23
references.pmid: 15607965
references.citation: Oncogene. 1996 Sep 5;13(5):1083-92
references.pmid: 8806698
references.citation: J Biol Chem. 2002 Oct 11;277(41):38230-8
references.pmid: 12151407
references.citation: Curr Mol Med. 2005 Mar;5(2):243-51
references.pmid: 15974879
references.citation: Virology. 2006 Jul 5;350(2):418-28
references.pmid: 16542696
references.citation: Mol Cancer Ther. 2006 Mar;5(3):541-55
references.pmid: 16546968
references.citation: Mol Cell Biol. 1999 Jun;19(6):4390-404
references.pmid: 10330179
references.citation: Mol Biol Cell. 2002 Aug;13(8):2585-97
references.pmid: 12181331
references.citation: Cancer Res. 2003 Feb 1;63(3):579-85
references.pmid: 12566299
references.citation: Cancer Gene Ther. 1999 Nov-Dec;6(6):554-63
references.pmid: 10608352
references.citation: Cancer Res. 2007 Feb 1;67(3):1299-307
references.pmid: 17283167
references.citation: J Virol. 2004 Nov;78(22):12243-51
references.pmid: 15507611
references.citation: Biochem Biophys Res Commun. 1999 Sep 24;263(2):361-5
references.pmid: 10491298
references.citation: Virology. 2004 Oct 10;328(1):52-61
references.pmid: 15380358